KERATOCONUS AND EPI-OFF CORNEAL CROSS-LINKING BY RIBOFLAVIN-ULTRAVIOLET TYPE A: INDICATIONS AND RATIONAL OF EMPLOYMENT


Submitted: 14 May 2012
Accepted: 14 May 2012
Published: 30 November 2010
Abstract Views: 677
PDF: 1400
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • A. Caporossi Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • C. Mazzotta Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • S. Baiocchi Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • O. Caporossi Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • R. Denaro Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • G. Cartocci Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
  • A. Paradiso Department Scienze Odontostomatologiche ed Oftalmologiche, Oculistic Section University Of Siena, Italy.
Keratoconus is the most common dystrophic corneal ectasia, characterized by the presence of irregular astigmatism associated with a reduction of corneal thickness. It is the leading cause of corneal transplant in Italy and Europe. Recently a new therapeutic opportunity is offered by Riboflavin + UV A Corneal Cross-linking, first introduced in Italy in 2004 by Professor Aldo Caporossi at the Department of Ophthalmology of Siena. This treatment requires early diagnosis to prevent corneal ectatic modifications related to pathology. The modern treatment of keratoconus is directed into three "directories": 1) prevention of its progression; 2) reduction of the related refractive defect and induced corneal aberrations; 3) replacement of ectatic corneal in advanced phase not subjected to conservative approach and HRGP lens intolerance. Riboflavin + UV A Collagen Cross-linking is mostly indicated in patients between 10 and 26 years old with progressive keratoconus (stage 1 and 2) with strict adherence to the recommended inclusion thickness (thinnest point > 400 microns).

Caporossi, A., Mazzotta, C., Baiocchi, S., Caporossi, O., Denaro, R., Cartocci, G., & Paradiso, A. (2010). KERATOCONUS AND EPI-OFF CORNEAL CROSS-LINKING BY RIBOFLAVIN-ULTRAVIOLET TYPE A: INDICATIONS AND RATIONAL OF EMPLOYMENT. Journal of the Siena Academy of Sciences, 2(2-IT), 61–63. https://doi.org/10.4081/jsas.2010.469

Downloads

Download data is not yet available.

Citations